Investors Conferences and FDA-Approved Products - Research Report on Baxter International, CR Bard, BD, Cooper, and Thoratec
NEW YORK, September 3, 2013 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), CR Bard Inc. (NYSE: BCR), Becton, Dickinson and Company (NYSE: BDX), The Cooper Companies Inc. (NYSE: COO), and Thoratec Corp. (NASDAQ: THOR). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.
Baxter International Inc. Research Report
On August 22, 2013, Baxter International Inc. (Baxter International) informed that it will participate at the Morgan Stanley Global Healthcare Conference on Monday, September 9, 2013 at 3:25 p.m. CT. Baxter International stated that interested parties can access a live webcast of its presentation via the Company website, while a replay of the same will be available until October 9, 2013. The Full Research Report on Baxter International Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/163d_BAX ]
CR Bard Inc. Research Report
On August 20, 2013, CR Bard Inc. (Bard) reported that it will participate at the Morgan Stanley Global Healthcare Conference in New York City on September 10, 2013, at 11:10 a.m. EDT. Bard informed that Timothy M. Ring, Chairman and CEO, will start the event by reviewing details regarding Bard via a presentation and interested parties can access a live audio webcast of this presentation, along with the Q&A Session, via the Bard's website. According to the Company, a replay of the webcast based on requirement can also be accessed after the completion of the event. The Full Research Report on CR Bard Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/141e_BCR ]
Becton, Dickinson and Company Research Report
On August 29, 2013, BD Rx Inc., a subsidiary of Becton, Dickinson and Company (BD), announced the approval of the third drug to be made available in the new BD Simplist™ line of ready-to-administer prefilled generic injectable. According to the Company, Ondansetron Injection, USP 4mg/2mL (2mg/mL) - an injectable antiemetic, was the drug approved by the US Food and Drug Administration (FDA). Mark Sebree, President, BD Rx, commented, "We're proud to be expanding our BD Simplist products with a drug like Ondansetron Injection, USP which is in high demand among clinicians and fills a need for an intervention that can be administered quickly. As we establish our product line with a third drug approval, we are seeing even further indication of the positive response to our new BD Simplist prefilled injectables especially among repeat customers." The Full Research Report on Becton, Dickinson and Company - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/0175_BDX ]
The Cooper Companies Inc. Research Report
On August 14, 2013, The Cooper Companies Inc. (Cooper) reported that it will participate at Baird's 2013 Health Care Conference in New York, New York on September 10, 2013, at 3:30 p.m. ET. Cooper informed that Albert G. White, III, Vice President and Chief Strategy Officer, will conduct a presentation to represent the Company and interested parties can access a live audio webcast of this presentation through the Company's Investor Relations website. The Full Research Report on The Cooper Companies Inc. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/9cde_COO ]
Thoratec Corp. Research Report
On August 22, 2013, Thoratec Corp. (Thoratec) announced that it will be presenting at the Morgan Stanley 2013 Health Care Conference on Monday, September 9, 2013, starting at 10:50 a.m., PDT (1:50 p.m., EDT). The Company stated that Taylor C. Harris, Vice President and CFO, will discuss updates of the Company and interested parties can access the presentation via the Company website. The Full Research Report on Thoratec Corp. - including full detailed breakdown, analyst ratings and price targets - is available to download free of charge at: [http://www.AnalystsCorner.com/r/full_research_report/1bee_THOR ]
- This is not company news. We are an independent source and our views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a best efforts basis and reviewed by a CFA. However, we are only human and are prone to make mistakes. If you notice any errors or omissions, please notify us below.
- This information is submitted as a net-positive to companies mentioned, to increase awareness for mentioned companies to our subscriber base and the investing public.
- If you wish to have your company covered in more detail by our team, or wish to learn more about our services, please contact us at pubco@EquityNewsNetwork.com.
- For any urgent concerns or inquiries, please contact us at compliance@EquityNewsNetwork.com.
- Are you a public company? Would you like to see similar coverage on your company? Send us a full investors' package to research@EquityNewsNetwork.com for consideration.
Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Equity News Network. An outsourced research services provider has, through Chartered Financial Analysts, only reviewed the information provided by Equity News Network in this article or report according to the Procedures outlined by Equity News Network. Equity News Network is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
NOT FINANCIAL ADVICE
Equity News Network makes no warranty, expressed or implied, as to the accuracy or completeness or fitness for a purpose (investment or otherwise), of the information provided in this document. This information is not to be construed as personal financial advice. Readers are encouraged to consult their personal financial advisor before making any decisions to buy, sell or hold any securities mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Equity News Network is not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted by Equity News Network whatsoever for any direct, indirect or consequential loss arising from the use of this document. Equity News Network expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Equity News Network does not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
SOURCE Analysts' Corner
More by this Source
Global Cell Therapy - Technologies, Markets and Companies
Jan 16, 2014, 14:00 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.